Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

plevitrexed

An orally bioavailable, small molecule, non-polyglutamatable, antifolate quinazoline derivative thymidine synthetase inhibitor with potential antineoplastic activity. Plevitrexed is transported into the cell via the physiological reduced folate carrier (RFC) system. Intracellularly, this agent selectively binds to the folate binding site of thymidylate synthase and inhibits thymidine synthesis, which may result in DNA synthesis inhibition and apoptosis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	BGC 9331 ZD9331
Chemical structure:	(2S)-2-[[4-[[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methy](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1H-tetrazol-5-yl)butanoic acid

plevitrexed

Search NCI's Drug Dictionary